Login to Your Account



Neurocrine Biosciences Brings In $200M In Oversold Public Offering

By Randall Osborne


Monday, September 15, 2003
Marching ahead with its non-benzodiazepine insomnia drug indiplon, Neurocrine Biosciences Inc. said it priced an offering of 3.75 million shares at $53 per share, for net proceeds of about $200 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription